Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results



Summary

The AMPLIFY-201 phase 1 trial evaluated a novel lymph node-targeted vaccine targeting the mKRAS mutation in patients with pancreatic and colorectal cancer. The vaccine, composed of an amphiphile designed to stimulate a potent immune response, was found to be safe and well-tolerated. Preliminary data demonstrated promising T-cell responses specific to the mKRAS target in a significant portion of patients. While the study primarily focused on safety and immunogenicity, some patients exhibited signs of clinical benefit, warranting further investigation. These results support continued development of this innovative vaccine approach for treating cancers driven by KRAS mutations.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!